[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611536":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":10,"locations":18,"responsibleParty":31,"collaborators":10,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":10,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Assiut University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Children with encephalitis",null,[12],"Diagnostic Test: CSF analysis and culture including S100B,Neuron Specific Enolase(NSE)",[14],{"type":15,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"DIAGNOSTIC_TEST","CSF analysis and culture including S100B,Neuron Specific Enolase(NSE)",[9],[19],{"facility":5,"status":10,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":10},"Asyut","Asyut Governorate","71717","Egypt","EG",{"type":26,"coordinates":27},"Point",[28,29],31.18368,27.18096,{"lat":29,"lon":28},{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Noha Mostafa Sayed Mostafa","Assistant Lecturer","100611536","clinicolaboratory-predictors-of-outcome-in-children-with-encephalitis-100611536",false,"NCT07241858","Clinicolaboratory Predictors of Outcome in Children With Encephalitis","encephalitis","Inclusion Criteria:\n\n* 1\\. Pediatric population aged 1month to 18 years.\n\n  * Decreased level of consciousness, personality change, or psychiatric manifestations lasting \\>24 h (in toddlers and infants, may present as increased irritability or lethargy)\n  * No alternative diagnosis to explain presentation\n  * Seizure (new onset)\n  * Fever (≥38.0°C)\n  * Focal neurologic findings (new onset)\n  * CSF WBC ≥5\u002Fmm3\n\nExclusion Criteria:\n\n* 1\\. Neonates and adults ( \\\u003C1 month or \\>18 years) 2. If they had a diagnosis of delirium or encephalopathy secondary to sepsis, toxins,renal ,hepatic or metabolic causes (hypoglycemia, electrolyte disturbances","ALL","1 Month","18 Years",{"count":46,"type":47},90,"ESTIMATED","OBSERVATIONAL",". A glycolytic enzyme called enolase is primarily found in neurons. A dimeric isoform of enolase called neuron-specific enolase (NSE) exists. It can be found in neurons, platelets, erythrocytes, and other neuroectodermal cells.It is one of the laboratory biomarkers that could be investigated in cases of encephalopathy, which can be found in both blood and cerebrospinal fluid, might be a helpful biomarker for determining brain injury prognosis and neuronal damage.(4) High S-100beta levels were associated with higher intensive care unit mortality and represented the strongest independent predictor of intensive care unit survival, whereas neuron-specific enolase (NSE) and the Glasgow Coma Scale failed to predict fatal outcome.(5) (NSE) and S100B are important as a diagnostic and a prognostic value in pediatric encephalopathy which is common and is potentially life threatening, previous studies were done worldwide to detect its diagnostic and prognostic value in acute encephalopathy among adult and pediatric age groups.(4) ,so we asses (NSE) and S100B to detect the the out come of acute encephalopathy",[51,52],"Encephalitis in Children","Encephalitis","NOT_YET_RECRUITING","2025-11-17",{"date":56,"type":57},"2025-11-21","ACTUAL",{"date":59,"type":47},"2026-01-01",{"date":61,"type":47},"2028-01-01",{"name":5,"class":6},1]